Lees A J
National Hospital for Nervous Diseases, London, UK.
Eur Neurol. 1987;27 Suppl 1:126-34. doi: 10.1159/000116207.
In an open pilot study, 10 patients with Parkinson's disease and nocturnal and/or early-morning disabilities were given Madopar HBS (hydrodynamically balanced system; mean dose 250 mg) shortly before retiring in addition to their usual daytime antiparkinsonian treatment. Eight patients derived worthwhile improvement; the most gratifying responses were seen in the relief of nocturnal bradykinesia, rigidity and tremor. Early-morning symptoms were also improved in 3 out of 5 patients, possibly as a secondary response to an improved nights sleep. Cramps, early-morning dystonia and pain, however, responded poorly. Overall results are sufficiently encouraging to warrant further controlled studies with Madopar HBS in what has been a relatively neglected area of distress for many patients with Parkinson's disease.
在一项开放性试验研究中，10名患有帕金森病且有夜间和/或清晨功能障碍的患者，除了接受常规的日间抗帕金森病治疗外，在睡前还加用了美多芭HBS（流体动力学平衡系统；平均剂量250毫克）。8名患者有显著改善；最令人满意的反应是夜间运动迟缓、僵硬和震颤得到缓解。5名患者中有3名的清晨症状也有所改善，这可能是夜间睡眠改善的继发反应。然而，痉挛、清晨肌张力障碍和疼痛的反应较差。总体结果足以令人鼓舞，有必要在帕金森病患者这一相对被忽视的痛苦领域，对美多芭HBS进行进一步的对照研究。
